CStone Pharma-B (02616) Rises Over 5% as Pralsetinib Included in National Reimbursement List; Company Expands 2.0 Pipeline

Stock News12-12

CStone Pharma-B (02616) surged more than 5%, reaching HK$6.07 by the time of writing, with a trading volume of HK$22.70 million. The increase follows the company's announcement that its RET inhibitor, GAVRETO® (pralsetinib capsules, 100 mg), has been successfully included in the latest National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration. The updated list will take effect on January 1, 2026.

To date, CStone Pharma has secured approvals for four innovative drugs, three of which—developed and registered in China—are now covered under the NRDL. A research report by TF Securities in August highlighted that pralsetinib's inclusion in the NRDL is expected to accelerate its market adoption.

CStone Pharma's preclinical pipeline includes over nine potential candidates, such as multispecific antibodies and ADCs, focusing on first-in-class (FIC) and best-in-class (BIC) research across oncology, autoimmune, and inflammatory diseases. The company's proprietary ADC technology platform, featuring optimized linkers for improved tumor-selective payload release, supports multiple ADC products in its Pipeline 2.0, providing sustained momentum for future growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119946536?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 11:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119946536","market":"nz","top_or_hot":-1,"title":"CStone Pharma-B (02616) Rises Over 5% as Pralsetinib Included in National Reimbursement List; Company Expands 2.0 Pipeline","media":"Stock News","content":"<p>CStone Pharma-B (02616) surged more than 5%, reaching HK$6.07 by the time of writing, with a trading volume of HK$22.70 million. The increase follows the company's announcement that its RET inhibitor, GAVRETO® (pralsetinib capsules, 100 mg), has been successfully included in the latest National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration. The updated list will take effect on January 1, 2026.</p>\n<p>To date, CStone Pharma has secured approvals for four innovative drugs, three of which—developed and registered in China—are now covered under the NRDL. A research report by TF Securities in August highlighted that pralsetinib's inclusion in the NRDL is expected to accelerate its market adoption.</p>\n<p>CStone Pharma's preclinical pipeline includes over nine potential candidates, such as multispecific antibodies and ADCs, focusing on first-in-class (FIC) and best-in-class (BIC) research across oncology, autoimmune, and inflammatory diseases. The company's proprietary ADC technology platform, featuring optimized linkers for improved tumor-selective payload release, supports multiple ADC products in its Pipeline 2.0, providing sustained momentum for future growth.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CStone Pharma-B (02616) Rises Over 5% as Pralsetinib Included in National Reimbursement List; Company Expands 2.0 Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCStone Pharma-B (02616) Rises Over 5% as Pralsetinib Included in National Reimbursement List; Company Expands 2.0 Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-12 11:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CStone Pharma-B (02616) surged more than 5%, reaching HK$6.07 by the time of writing, with a trading volume of HK$22.70 million. The increase follows the company's announcement that its RET inhibitor, GAVRETO® (pralsetinib capsules, 100 mg), has been successfully included in the latest National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration. The updated list will take effect on January 1, 2026.</p>\n<p>To date, CStone Pharma has secured approvals for four innovative drugs, three of which—developed and registered in China—are now covered under the NRDL. A research report by TF Securities in August highlighted that pralsetinib's inclusion in the NRDL is expected to accelerate its market adoption.</p>\n<p>CStone Pharma's preclinical pipeline includes over nine potential candidates, such as multispecific antibodies and ADCs, focusing on first-in-class (FIC) and best-in-class (BIC) research across oncology, autoimmune, and inflammatory diseases. The company's proprietary ADC technology platform, featuring optimized linkers for improved tumor-selective payload release, supports multiple ADC products in its Pipeline 2.0, providing sustained momentum for future growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02616","symbol_name":"基石药业-B","start_time":0,"source_url":"","article_id":"1119946536","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119946536","pubTimestamp":1765509254,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CStone Pharma-B (02616) surged more than 5%, reaching HK$6.07 by the time of writing, with a trading volume of HK$22.70 million. The increase follows the company's announcement that its RET...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02616":"基石药业-B","BK1574":"生物医药B类股","BK1161":"生物科技"},"translate_title":"基石药业-B(02616)涨超5%，普拉替尼纳入国家报销目录；公司扩大2.0管道","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":1},"content_text":"CStone Pharma-B (02616) surged more than 5%, reaching HK$6.07 by the time of writing, with a trading volume of HK$22.70 million. The increase follows the company's announcement that its RET inhibitor, GAVRETO® (pralsetinib capsules, 100 mg), has been successfully included in the latest National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration. The updated list will take effect on January 1, 2026.\nTo date, CStone Pharma has secured approvals for four innovative drugs, three of which—developed and registered in China—are now covered under the NRDL. A research report by TF Securities in August highlighted that pralsetinib's inclusion in the NRDL is expected to accelerate its market adoption.\nCStone Pharma's preclinical pipeline includes over nine potential candidates, such as multispecific antibodies and ADCs, focusing on first-in-class (FIC) and best-in-class (BIC) research across oncology, autoimmune, and inflammatory diseases. The company's proprietary ADC technology platform, featuring optimized linkers for improved tumor-selective payload release, supports multiple ADC products in its Pipeline 2.0, providing sustained momentum for future growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119946536","isCrawlerRequest":true}